Skip to main content
. 2018 Feb 5;20(9):1231–1239. doi: 10.1093/neuonc/noy015

Fig. 3.

Fig. 3

T1 MRI following administration of gadolinium enhancement in a responder. (A) Day −61 imaging showing tumor features while on Avastin. (B) Progression on Avastin at day −3 with extension within the frontal lobe (thin arrow) and corpus collosum (thick arrow). (C) Response with decreased enhancement at day 43 (right). Patient had no interruption in Bev therapy prior to initiating Evo.